Process Development and Manufacture of the Core Starting Material of Adagrasib (MRTX849)-Reference-Cited by-同舟云学术

Process Development and Manufacture of the Core Starting Material of Adagrasib (MRTX849)

Published:2024-01-26 Issue: Volume: Page:
ISSN:1083-6160
Container-title:Organic Process Research & Development
language:en
Short-container-title:Org. Process Res. Dev.

Author:

Scattolin Thomas¹^ORCID,Paymode Dinesh Jagannath¹^ORCID,Snead David Robinson¹^ORCID,Lu Zhichao¹,Yu Stanley¹^ORCID,Robert-Monpate Maxime²,Chao Maria Noelia²,Haas Thomas Michael³,Wang Hanhui⁴,Liang Xuewei⁵,Chen Cheng-yi¹^ORCID

Affiliation:

1. Mirati Therapeutics, 3545 Cray Court, San Diego, California 92121, United States

2. Euroapi France, 4 La Paterie, 63480 Vertolaye, France

3. Euroapi Germany GmbH, 65926 Frankfurt am Main, Germany

4. PharmaBlock Sciences (Nanjing), Inc., No. 81 Huasheng Road, Jiangbei New Area, Nanjing, Jiangsu 210032, P. R. China

5. PharmaBlock Sciences (Nanjing), Inc., No. 11, Weiqi Road, Hangzhou Bay Shangyu Economic and Technological Development Area, Shaoxing, Zhejiang 312366, P. R. China

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Physical and Theoretical Chemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.oprd.3c00485

Reference19 articles.

1. Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer

2. Development of Adagrasib’s Commercial Manufacturing Route

3. Synthesis of Adagrasib (MRTX849), a Covalent KRAS^G12C Inhibitor Drug for the Treatment of Cancer

4. A new mode of reactivity of N-methoxy-N-methylamides with strongly basic reagents

5. Organophotocatalytic N–O Bond Cleavage of Weinreb Amides: Mechanism-Guided Evolution of a PET to ConPET Platform